Charting the "Splice" Routes to MDS

Esther A Obeng; Benjamin L Ebert

doi:10.1016/j.ccell.2015.04.016

Charting the "Splice" Routes to MDS

Cancer Cell. 2015 May 11;27(5):607-9. doi: 10.1016/j.ccell.2015.04.016.

Authors

Esther A Obeng¹, Benjamin L Ebert²

Affiliations

¹ Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA; Dana-Farber Cancer Institute, Boston, MA 02115, USA; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
² Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA; Dana-Farber Cancer Institute, Boston, MA 02115, USA. Electronic address: [email protected].

PMID: 25965565
DOI: 10.1016/j.ccell.2015.04.016

Abstract

Mutations in components of the 3' mRNA splicing machinery are found in almost 50% of myelodysplastic syndrome (MDS) cases. In this issue of Cancer Cell, Kim and colleagues, Colla and colleagues, and Shirai and colleagues report on the impact of mutated or dysregulated splicing factors to hematopoiesis, mRNA splicing, and MDS pathogenesis.

Publication types

Comment

MeSH terms

Animals
Cell Differentiation / genetics*
Exons*
Hematopoiesis / genetics*
Humans
Mutation*
Myelodysplastic Syndromes / genetics*
Nuclear Proteins / genetics*
RNA Precursors / genetics*
RNA Splicing / genetics*
RNA, Messenger / genetics*
Ribonucleoproteins / genetics*
Telomere*

Substances

Nuclear Proteins
RNA Precursors
RNA, Messenger
Ribonucleoproteins